Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: The BioCycle Study

American Journal of Epidemiology

Volumn 175, Issue 5, 2012, Pages 423-431

  Gaskins, Audrey J ^a   Wilchesky, Machelle ^b   Mumford, Sunni L ^a   Whitcomb, Brian W ^c   Browne, Richard W ^d   Wactawski Wende, Jean ^e   Perkins, Neil J ^a   Schisterman, Enrique F ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

estrogens; inflammation; menstrual cycle

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE;

AGE CLASS; CARDIOVASCULAR DISEASE; FERTILITY; HEALTH RISK; HORMONE; PHYSIOLOGY; PROTEIN; REPRODUCTIVE CYCLE; WOMENS HEALTH;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; NORMAL HUMAN; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INFLAMMATION; LINEAR MODELS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; PROGESTERONE; PROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

NEW YORK [UNITED STATES]; UNITED STATES;

EID: 84857554633     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr343     Document Type: Article

References (40)

1. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47 (3):403-411.
2. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2006;187 (2):415-422.
3. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288 (8):980-987.
4. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342 (12):836-843.
5. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003;88 (6):2470-2478.
6. Mukamal KJ, Muller JE, Maclure M, et al. Variation in the risk of onset of acute myocardial infarction during the menstrual cycle. Am J Cardiol. 2002;90 (1):49-51.
7. Hamelin BA, Méthot J, Arsenault M, et al. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women. Am J Med. 2003;114 (7):599-602.
8. Chakrabarti S, Lekontseva O, Davidge ST. Estrogen is a modulator of vascular inflammation. IUBMB Life. 2008;60 (6):376-382.
9. Gray GA, Sharif I, Webb DJ, et al. Oestrogen and the cardiovascular system: the good, the bad and the puzzling. Trends Pharmacol Sci. 2001;22 (3):152-156.
10. Prestwood KM, Unson C, Kulldorff M, et al. The effect of different doses of micronized 17b-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci. 2004;59 (8):827-832.
11. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation. 2002;106 (10):1224-1228.
12. Ropponen A, Aittomäki K, Vihma V, et al. Effects of oral and transdermal estradiol administration on levels of sex hormonebinding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab. 2005;90 (6):3431-3434.
13. Wander K, Brindle E, O'Connor KA. C-reactive protein across the menstrual cycle. Am J Phys Anthropol. 2008;136 (2):138-146.
14. Blum CA, Müller B, Huber P, et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab. 2005;90 (6):3230-3235.
15. Jilma B, Dirnberger E, Löscher I, et al. Menstrual cycle associated changes in blood levels of interleukin-6, a1 acid glycoprotein, and C-reactive protein. J Lab Clin Med. 1997;130 (1):69-75.
16. Capobianco G, de Muro P, Cherchi GM, et al. Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles. Arch Gynecol Obstet. 2010;282 (2):207-213.
17. Wunder DM, Yared M, Bersinger NA, et al. Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. Eur J Endocrinol. 2006;155 (1):137-142.
18. Wactawski-Wende J, Schisterman EF, Hovey KM, et al. Bio-Cycle Study: design of the longitudinal study of the oxidative stress and hormone variation during the menstrual cycle. BioCycle Study Group. Paediatr Perinat Epidemiol. 2009;23 (2):171-184.
19. Howards PP, Schisterman EF, Wactawski-Wende J, et al. Timing clinic visits to phases of the menstrual cycle by using a fertility monitor: the BioCycle Study. Am J Epidemiol. 2009;169 (1):105-112.
20. Gaskins AJ, Mumford SL, Zhang C, et al. Effect of daily fiber intake on reproductive function: the BioCycle Study. BioCycle Study Group. Am J Clin Nutr. 2009;90 (4):1061-1069.
21. Whitcomb BW, Bodach SD, Mumford SL, et al. Ovarian function and cigarette smoking. Paediatr Perinat Epidemiol. 2010;24 (5):433-440.
22. Browne RW, Bloom MS, Schisterman EF, et al. Analytical and biological variation of F2-isoprostanes during the menstrual cycle. Clin Chem. 2009;55 (6):1245-1247.
23. Rifai N, Ballantyne CM, Cushman M, et al. Point: highsensitivity C-reactive protein and cardiac C-reactive protein assays: is there a need to differentiate? Clin Chem. 2006;52 (7):1254-1256.
24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107 (3):499-511.
25. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107 (3):363-369.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18 (6):499-502.
27. Craig CL, Marshall AL, Sjöström M, et al. International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35 (8):1381-1395.
28. Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47 (3):444-450.
29. Little RJ, Rubin DB. Statistical Analysis With Missing Data. 2nd ed. New York, NY: J. Wiley & Sons; 2002.
30. Littell RC, Henry PR, Ammerman CB. Statistical analysis of repeated measures data using SAS procedures. J Anim Sci. 1998;76 (4):1216-1231.
31. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11 (5):550-560.
32. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168 (6):656-664.
33. Critchley HO, Kelly RW, Brenner RM, et al. The endocrinology of menstruation-a role for the immune system. Clin Endocrinol (Oxf). 2001;55 (6):701-710.
34. MacRitchie AN, Jun. SS, Chen Z, et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997;81 (3):355-362.
35. Kubes P, Kurose I, Granger DN. No donors prevent integrininduced leukocyte adhesion but not P-selectin-dependent rolling in postischemic venules. Am J Physiol. 1994;267(3 pt 2):H931-H937.
36. Srivastava S, Weitzmann MN, Cenci S, et al. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun. and JunD. J Clin Invest. 1999;104 (4):503-513.
37. Korpelainen EI, Gamble JR, Smith WB, et al. The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci U S A. 1993;90 (23):11137-11141.
38. Lu A, Frink M, Choudhry MA, et al. Mitochondria play an important role in 17β-estradiol attenuation of H (2) O (2) - induced rat endothelial cell apoptosis. Am J Physiol Endocrinol Metab. 2007;292 (2):E585-E593.
39. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11 (4):411-423.
40. Roberts CW, Walker W, Alexander J. Sex-associated hormones and immunity to protozoan parasites. Clin Microbiol Rev. 2001;14 (3):476-488.